OSBORNE DAVID W
Known title: Chief Technical OfficerCIK: 0001252999
Associated companies
Transaction History
| ARQT | ▼ Sell | Open Market | 690 | $11K | 3/6/2023 | View on chart |
| ARQT | ▼ Sell | Open Market | 15 | $248 | 3/2/2023 | View on chart |
| ARQT | ▼ Sell | Open Market | 1,198 | $19K | 3/2/2023 | View on chart |
| ARQT | ▲ Buy | Grant | 14,900 | $0 | 3/2/2023 | View on chart |
| ARQT | ▼ Sell | Open Market | 792 | $13K | 2/28/2023 | View on chart |
| ARQT | ▼ Sell | Open Market | 2,197 | $56K | 7/8/2022 | View on chart |
| ARQT | ▼ Sell | Open Market | 2,197 | $45K | 4/21/2022 | View on chart |
| ARQT | ▼ Sell | Open Market | 28 | $460 | 3/7/2022 | View on chart |
| ARQT | ▼ Sell | Open Market | 828 | $14K | 3/4/2022 | View on chart |
| ARQT | ▲ Buy | Grant | 13,300 | $0 | 3/3/2022 | View on chart |
| ARQT | ▼ Sell | Open Market | 775 | $14K | 3/1/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 11, 2026
ARQT Highlights New ZORYVE Data, Wins Beauty Award, Faces Downgrade
Arcutis Biotherapeutics presented fresh clinical data for its topical drug ZORYVE at the EADV and Fall Clinical conferences, adding real‑world evidence on its use for inflammatory skin conditions. The company also received a 2026 Marie Claire Beauty Award for ZORYVE, highlighting its potential beyond dermatology. Meanwhile, analysts have downgraded the stock, citing a shrinking valuation multiple. These developments suggest the market is reassessing the company’s growth prospects.
ARQT Highlights New ZORYVE Data, Wins Beauty Award, Faces Downgrade. Arcutis Biotherapeutics presented fresh clinical data for its topical drug ZORYVE at the EADV and Fall Clinical conferences, adding real‑world evidence on its use for inflammatory skin conditions. The company also received a 2026 Marie Claire Beauty Award for ZORYVE, highlighting its potential beyond dermatology. Meanwhile, analysts have downgraded the stock, citing a shrinking valuation multiple. These developments suggest the market is reassessing the company’s growth prospects.